Genspera, Inc. Featured in TheStockRadio.com Interview

SAN ANTONIO, Dec. 2, 2014 /PRNewswire/ -- GenSpera, Inc. (OTCQB: GNSZ), a leader in developing innovative prodrug therapeutics for the treatment of cancer, releases a recent audio interview with TheStockRadio.com. Craig Dionne, PhD, GenSpera's CEO, discusses the company's background and history including the inception and development of the company's lead compound, mipsagargin, at John Hopkins University and its subsequent development by the company. Dr. Dionne also highlights the benefits of mipsagargin over traditional chemotherapeutics, including its limited side effects and more effective tumor killing properties. 

Finally, Dr. Dionne provides an update as to the company's current Phase II clinical trials in liver cancer and glioblastoma (brain cancer) as well as future Phase II clinical trials in prostate cancer and kidney cancer and possibly even lung and breast cancers that have metastasized to the brain.

All information discussed has been publicly disclosed in press releases and filings.    

Hear the full interview here: http://thestockradio.com/gnsz-genspera-inc-pres-ceo-craig-dionne/

Learn more about TheStockRadio.com

http://thestockradio.com

About GenSpera

GenSpera's technology platform combines a powerful, plant-derived cytotoxin (thapsigargin) with a prodrug delivery system that provides for the targeted release of drug candidates within a tumor. Unlike typical chemotherapeutic agents, thapsigargin results in cell death irrespective of the rate of cell division, which may provide an effective approach to kill both fast- and slow-growing cancers. GenSpera's lead drug candidate, mipsagargin, is activated by the enzyme PSMA, which is found at high levels in the vasculature of liver and glioblastoma cancers and in the vasculature of almost all other solid tumors. Mipsagargin is expected to have potential efficacy in a wide variety of tumor types.

The US Food and Drug Administration (FDA) granted Orphan Drug designation in 2013 for the evaluation of mipsagargin in patients with hepatocellular carcinoma (liver cancer). Mipsagargin Phase II clinical trials are underway in both hepatocellular carcinoma and glioblastoma patients (brain cancer).

For more information, please visit the company's website: www.genspera.com or follow us on Twitter @GenSperaNews.

Company presentations are available at: http://www.genspera.com/

Cautionary Statement Regarding Forward Looking Information

This news release may contain forward-looking statements. Investors are cautioned that statements in this press release regarding potential applications of GenSpera's technologies constitute forward-looking statements that involve risks and uncertainties, including, without limitation, risks inherent in the development and commercialization of potential products, uncertainty of clinical trial results or regulatory approvals or clearances, need for future capital, dependence upon collaborators and maintenance of our intellectual property rights. Actual results may differ materially from the results anticipated in these forward-looking statements. Additional information on potential factors that could affect our results and other risks and uncertainties will be detailed from time to time in GenSpera's periodic reports filed with the Securities and Exchange Commission.

CONTACT:                  

Company:
Craig Dionne, PhD, CEO
GenSpera, Inc.  +1-(210)479-8112

Investor Relations: 
Steve Gersten
Capital Markets Group
[email protected]
+1-813-926-8920

Media:
D. Van Zant
+1-(800) 665-0411

To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/genspera-inc-featured-in-thestockradiocom-interview-300003253.html

SOURCE GenSpera, Inc.

Suggested Articles

Pfizer is doubling down on real-world data in HR-positive, HER2-negative breast cancer patients to boost its case for blockbuster Ibrance.

Sanofi, which has moved purposefully into high technologies to get more from its manufacturing, will lean even more on that strategy to save costs.

In a last-minute deal during North American trade talks, the Trump administration agreed to scrap rules protecting biologic drugs from copycat rivals.